GRIT Biotechnology Named to the '2024 GEI China Potential Unicorn Enterprises' List

Recently, Great Wall Strategy Consulting released the "GEI China Potential Unicorn Enterprise Research Report 2024".Gravel BiotechWith advantages in team and industry direction, technological innovation capabilities, and development trends,Ranked on the "2024 GEI China Potential Unicorn Enterprises" List。

Potential unicorn companies are the reserve force of unicorn companies, the leaders of new tracks, and the rising stars with greater development potential and growth.GEI believes that potential unicorn companies are reshaping the value chain with new technologies and models,开拓新市场、创造新业态 through scenario innovation, and are playing an increasingly important role in leading new tracks, promoting high-quality regional economic development, and driving the transformation of old and new drivers.

Grit Bio's inclusion in this list not only demonstrates the high recognition from the capital market and the industry regarding the development prospects of tumor immunotherapy, but also fully proves Grit Bio's breakthrough innovation capabilities in multiple R&D pipelines, represented by Tumor Infiltrating Lymphocyte (TIL) drugs.

About Grail Bio

Grail Bio was founded in 2019 as an innovative pharmaceutical company focused on tumor immunotherapy and TIL drug development pipelines. Grail Bio has completed multiple rounds of equity financing, receiving support from several well-known domestic and international venture capital funds. GT101 Injection, independently developed by Grail Bio, is the first TIL drug in China to be approved for clinical registration and is currently in a pivotal Phase II clinical trial. GT201 Injection, Grail Bio's globally first membrane-bound IL-15 complex-edited TIL product, has completed dual clinical trial applications in both China and the U.S. The company’s core R&D platforms include the StemTexp® Stem-like TIL Expansion Technology Platform, StaViral® Stable Viral Vector Process, ImmuT Finder® Immunomodulatory Target Discovery Platform, and KOReTIL® High-efficiency Gene Knockout System, which have enabled the development of a series of next-generation gene-edited TIL drugs. Grail Bio possesses internationally leading technical reserves and industrial resources, aiming to create groundbreaking cellular therapies for solid tumors, bringing new hope to cancer patients.